Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.
A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.
Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.
Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.
Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.
Precision BioSciences (Nasdaq: DTIL) announced an accepted abstract for poster presentation at the 64th American Society of Hematology Annual Meeting in New Orleans from December 10-13, 2022. The poster will detail the effective cell dose and functional attributes of its lead CD19 candidate, Azercabtagene Zapreleucel (azer-cel), in treating relapsed or refractory non-Hodgkin lymphoma. This analysis highlights the product's composition and cell doses, which may improve safety and efficacy. Dr. Alan List emphasized the significance of maximizing naïve cell phenotype in allogeneic CAR T therapy.
Precision BioSciences, Inc. (Nasdaq: DTIL) has announced plans to publish its financial results for the third quarter of 2022 on November 8, 2022, along with a business update. The company focuses on developing ex vivo allogeneic CAR T and in vivo gene editing therapies using its proprietary ARCUS® genome editing platform. This platform is designed for therapeutic safety and versatility and aims to address genetic and infectious diseases lacking effective treatments.
Precision BioSciences (Nasdaq: DTIL) announced an inducement grant for Michael Amoroso, its CEO, under the 2021 Employment Inducement Incentive Award Plan. This grant includes an option to purchase 250,000 shares at a price of $1.38, with 25% vesting on October 15, 2023, and the remainder vesting over three years. The grant complies with Nasdaq Listing Rules as material to Mr. Amoroso's employment. Precision BioSciences specializes in gene editing therapies using its proprietary ARCUS® platform, targeting genetic and infectious diseases.
Summary not available.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced its participation in the Jefferies Cell & Genetic Medicine Summit on September 30, 2022, at 2:00 PM ET, located at the Lotte New York Palace Hotel. A recorded webcast will be available on the company’s website shortly after the presentation, with an archived replay accessible for 30 days. The company focuses on developing innovative gene editing therapies using its proprietary ARCUS® platform, targeting genetic and infectious diseases lacking effective treatments. For further details, visit www.precisionbiosciences.com.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A fireside chat is scheduled for September 13, 2022, at 4:30 PM ET, located at the Lotte New York Palace Hotel. The session will be available via a recording on Precision's website the next day, with an archived replay for 30 days. Precision BioSciences focuses on gene editing using its ARCUS® platform to develop CAR T and gene editing therapies for genetic and infectious diseases.
Precision BioSciences (NASDAQ: DTIL) announced organizational changes, promoting Cindy Atwell to Chief Business Officer, Jeff Smith to Chief Research Officer, and Derek Jantz to focus on company strategy as Chief Scientific Officer. These changes aim to enhance leadership and align responsibilities in advancing the company's ARCUS-based ex vivo CAR T and in vivo gene editing therapies. CEO Michael Amoroso expressed confidence in the leadership team’s commitment to patients and the company’s growth towards becoming a commercial stage entity.
Precision BioSciences, Inc. (DTIL) announced key developments in its second quarter 2022 update. The company launched a collaboration with Novartis for an in vivo gene insertion treatment targeting hemoglobinopathies. They reported a cash balance of approximately $184.1 million, extending their financial runway through 2024. Interim results from the PBCAR0191 CAR T study showed a 100% overall response rate among relapsed subjects. However, total revenues fell to $3.8 million, down $65 million year-over-year, primarily due to the absence of previous revenues from the Servier Agreement.
Precision BioSciences (NASDAQ: DTIL) will release its Q2 2022 financial results and provide a business update on August 8, 2022. The company is focused on advancing its proprietary ARCUS® genome editing platform, which targets both ex vivo CAR T immunotherapies and in vivo gene editing therapies. Precision BioSciences aims to address genetic and infectious diseases lacking adequate treatments, showcasing its commitment to therapeutic safety and delivery.
Precision BioSciences (Nasdaq: DTIL) announced on July 19, 2022, that its Compensation Committee has approved inducement awards for new employees. A total of 583,302 stock options were granted under the 2021 Employment Inducement Incentive Award Plan. The options have an exercise price of $1.54 and will vest over four years, beginning with 25% after the first year. This decision reflects the company's strategy to attract talent while advancing its ARCUS-based gene editing therapies aimed at treating genetic diseases.